Apogee Therapeutics, Inc.
$90.92
▲
0.12%
2026-04-21 05:20:01
www.apogeetherapeutics.com
NGM: APGE
Explore Apogee Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$6.41 B
Current Price
$90.92
52W High / Low
$95.31 / $31.38
Stock P/E
—
Book Value
$13.21
Dividend Yield
—
ROCE
-31.41%
ROE
-31.57%
Face Value
—
EPS
$-4.22
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
261
Beta
1.02
Debt / Equity
0.98
Current Ratio
26.57
Quick Ratio
26.57
Forward P/E
-15.83
Price / Sales
—
Enterprise Value
$5.22 B
EV / EBITDA
-18.36
EV / Revenue
—
Rating
Strong Buy
Target Price
$116.87
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Seres Therapeutics, Inc. | $8.94 | 15.05 | $85.7 M | — | -79.05% | 19.64% | $29.98 / $6.53 | $4.63 |
| 2. | Benitec Biopharma Inc. | $13.99 | — | $483.71 M | — | -42.71% | -33.5% | $17.15 / $9.85 | $5.47 |
| 3. | Travere Therapeutics, Inc. | $40.29 | — | $3.72 B | — | -14.11% | -57.8% | $43.31 / $13.88 | $1.26 |
| 4. | Surrozen, Inc. | $32.25 | — | $362.52 M | — | -47.4% | 231.45% | $33.22 / $5.9 | $-19.21 |
| 5. | Bio-Techne Corporation | $59.22 | 116.91 | $9.33 B | 0.53% | 10.19% | 3.97% | $72.16 / $46.01 | $12.9 |
| 6. | Absci Corporation | $3.95 | — | $547.82 M | — | -64.8% | -62.5% | $5.23 / $2.24 | $1.25 |
| 7. | Tvardi Therapeutics, Inc. | $3.22 | — | $30.72 M | — | -127.18% | -2.38% | $43.65 / $2.75 | $2.23 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -78.06 M | -71.28 M | -73.17 M | -63.1 M | -75.88 M | — |
| Net Profit | -69.39 M | -65.02 M | -66.1 M | -55.34 M | -67.22 M | — |
| EPS in Rs | -1.14 | -1.06 | -1.08 | -0.91 | -1.1 | -0.86 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -285.6 M | -216.87 M | -93 M | -30.73 M |
| Net Profit | -255.84 M | -182.15 M | -83.98 M | -39.78 M |
| EPS in Rs | -4.19 | -2.98 | -1.37 | -0.65 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 937.13 M | 753.95 M | 401.4 M | 152.06 M |
| Total Liabilities | 33.25 M | 37.16 M | 21.49 M | 9.98 M |
| Equity | 903.88 M | 716.79 M | 379.91 M | 0 M |
| Current Assets | 741.36 M | 529.71 M | 398.41 M | 152.06 M |
| Current Liabilities | 27.91 M | 28.56 M | 20.56 M | 9.98 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -227.45 M | -171.17 M | -74.76 M | -16.43 M |
| Investing CF | -179.57 M | -300.46 M | -273.91 M | 0 M |
| Financing CF | 396.49 M | 495.11 M | 315.39 M | 168.32 M |
| Free CF | -232.6 M | -172.33 M | -74.93 M | -16.43 M |
| Capex | -5.15 M | -1.15 M | -0.17 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -40.46% | -116.88% | -111.1% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.